georgie18
2 meses hace
SGMO...$1.45...🥳...Off my $1.03 Dip Alert...
georgie18
Member Level
Re: georgie18 post# 670316
Monday, January 06, 2025 9:52:15 AM
Post#
670503
of 670675
SGMO...$1.35s clearing here off my $1.03 Dip Alert...🥳
georgie18
Member Level
Re: georgie18 post# 996
Friday, January 03, 2025 2:29:51 PM
Post#
997
of 999
SGMO...$1.28s clearing here...🥳...Off the $1.03...Dip Alert...
georgie18
Member Level
Re: georgie18 post# 670026
Friday, January 03, 2025 8:31:17 AM
Post#
670182
of 670314
SGMO...$1.13s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 985
Thursday, January 02, 2025 9:42:07 AM
Post#
992
of 995
SGMO...$1.03...🥳...Loading down here...Took a dip... Pfizer terminated partnership...
georgie18
2 meses hace
SGMO...$1.35s clearing here off my $1.03 Dip Alert...🥳
georgie18
Member Level
Re: georgie18 post# 996
Friday, January 03, 2025 2:29:51 PM
Post#
997
of 999
SGMO...$1.28s clearing here...🥳...Off the $1.03...Dip Alert...
georgie18
Member Level
Re: georgie18 post# 670026
Friday, January 03, 2025 8:31:17 AM
Post#
670182
of 670314
SGMO...$1.13s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 985
Thursday, January 02, 2025 9:42:07 AM
Post#
992
of 995
SGMO...$1.03...🥳...Loading down here...Took a dip... Pfizer terminated partnership...
georgie18
4 meses hace
SGMO...$2.53...Fins after close...🥳
georgie18
Member Level
Re: georgie18 post# 664188
Friday, November 08, 2024 11:09:45 AM
Post#
664225
of 664553
SGMO...$3.10s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 385366
Friday, November 08, 2024 9:21:06 AM
Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...
georgie18
Member Level
Re: georgie18 post# 663989
Thursday, November 07, 2024 2:23:36 PM
Post#
664113
of 664186
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$3.10s clearing here...🥳
georgie18
Member Level
Re: georgie18 post# 385366
Friday, November 08, 2024 9:21:06 AM
Post#
385382
of 385395
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...
georgie18
Member Level
Re: georgie18 post# 663989
Thursday, November 07, 2024 2:23:36 PM
Post#
664113
of 664186
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$3...🥳...Been waiting for this ..."W" in play here...$6 target for me...
georgie18
Member Level
Re: georgie18 post# 663989
Thursday, November 07, 2024 2:23:36 PM
Post#
664113
of 664186
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.83...🥳
georgie18
Member Level
Re: georgie18 post# 385311
Thursday, November 07, 2024 9:59:59 AM
Post#
385341
of 385365
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.65s clearing here...This was as low as .30 in July...🥳
georgie18
Member Level
Re: georgie18 post# 663756
Wednesday, November 06, 2024 2:50:09 PM
Post#
663878
of 663987
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.45...HOD..."W" Pattern in play here...Target $6...🥳https://schrts.co/dEUXVUBf
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.25...🥳
georgie18
Member Level
Re: georgie18 post# 663703
Tuesday, November 05, 2024 3:35:51 PM
Post#
663735
of 663755
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.14...HOD...🥳
georgie18
Member Level
Re: georgie18 post# 663630
Tuesday, November 05, 2024 1:25:37 PM
Post#
663703
of 663733
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
georgie18
4 meses hace
SGMO...$2.02...🥳...On Tuesday, H.C. Wainwright adjusted its outlook on shares of Sangamo BioSciences (NASDAQ:SGMO), raising the price target to $10 from the previous $5, while maintaining a Buy rating on the company's stock. The revision follows Sangamo's announcement on October 22, 2024, regarding a productive Type B meeting with the FDA about its gene therapy program for Fabry disease, isaralgagene civaparvovec (ST-920 or isa-vec).
The FDA has acknowledged that data from the ongoing Phase 1/2 STAAR trial could serve as the primary evidence for an accelerated approval process. This development could lead to a faster and more cost-effective path to submitting a Biologics License Application (BLA) than initially anticipated.
Member Level
Re: georgie18 post# 663012
Monday, November 04, 2024 4:27:39 PM
Post#
663630
of 663703
SGMO...$1.77...Fins will be announced after close on Nov 12,2024...🥳
- U.S. Food and Drug Administration (FDA) provides a clear regulatory pathway to Accelerated Approval for isaralgagene civaparvovec using data from ongoing Phase 1/2 STAAR study, avoiding requirement for additional registrational study and accelerating estimated time to potential approval by approximately three years.
- FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway.
- Data to support Accelerated Approval pathway available in first half of 2025, with a potential Biologics License Application (BLA) submission expected in the second half of 2025.
Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
Monksdream
3 semanas hace
glenn1919
2 meses hace
PonkenPlonken
2 meses hace
jimr1717
2 meses hace
jondoeuk
2 meses hace
Mactheriverrat
3 meses hace
molee
4 meses hace
INV4
4 meses hace
Hot Features
Premium
